• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Prescriptions in Type 2 Diabetes by Kidney and Cardiovascular Disease.

作者信息

Mehta Sneha S, Surapaneni Aditya L, Pandit Krutika, Xu Yunwen, Horwitz Leora, Blecker Saul, Blum Matthew F, Chang Alexander R, Shin Jung-Im, Grams Morgan E

机构信息

Department of Medicine, NYU Grossman School of Medicine, New York, New York.

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

出版信息

J Am Soc Nephrol. 2025 Feb 1;36(2):290-292. doi: 10.1681/ASN.0000000585. Epub 2024 Nov 27.

DOI:10.1681/ASN.0000000585
PMID:39688374
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11801770/
Abstract
摘要

相似文献

1
Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter 2 Inhibitor Prescriptions in Type 2 Diabetes by Kidney and Cardiovascular Disease.2型糖尿病患者中基于肾脏和心血管疾病的胰高血糖素样肽-1受体激动剂及钠-葡萄糖协同转运蛋白2抑制剂处方情况
J Am Soc Nephrol. 2025 Feb 1;36(2):290-292. doi: 10.1681/ASN.0000000585. Epub 2024 Nov 27.
2
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD.胰高血糖素样肽-1受体激动剂与钠/葡萄糖协同转运蛋白2抑制剂在预防2型糖尿病合并慢性肾脏病患者慢性肾衰竭及死亡方面的比较疗效
Am J Kidney Dis. 2025 Apr 29. doi: 10.1053/j.ajkd.2025.03.016.
3
Comparison of New-Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, or Glucagon-Like Peptide-1 Agonists: A Population-Based Cohort Study.2型糖尿病患者中使用钠-葡萄糖协同转运蛋白2抑制剂、二肽基肽酶4抑制剂或胰高血糖素样肽1激动剂后新发外周动脉疾病的比较：一项基于人群的队列研究。
J Am Heart Assoc. 2025 Jun 3;14(11):e034175. doi: 10.1161/JAHA.123.034175. Epub 2025 May 22.
4
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
5
Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial).改善 1 型糖尿病的肥胖治疗（OTID）：胰高血糖素样肽 1 类似物和钠-葡萄糖共转运蛋白 2 抑制剂联合治疗的随机对照试验——改善 1 型糖尿病的肥胖治疗（OTID 试验）方案。
Trials. 2024 Feb 16;25(1):129. doi: 10.1186/s13063-024-07930-3.
6
Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.在 2 型糖尿病中应用胰高血糖素样肽-1 受体激动剂联合钠-葡萄糖协同转运蛋白 2 抑制剂的实用考量和原理。
Can J Diabetes. 2021 Apr;45(3):291-302. doi: 10.1016/j.jcjd.2020.09.005. Epub 2020 Sep 14.
7
Beyond glycemic control: Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease.超越血糖控制：钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂在糖尿病肾病中的作用
World J Diabetes. 2025 Jun 15;16(6):104706. doi: 10.4239/wjd.v16.i6.104706.
8
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
9
Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.基于心血管或肾脏结局试验的 2 型糖尿病患者中 5 种钠-葡萄糖共转运蛋白 2 抑制剂和 7 种胰高血糖素样肽 1 受体激动剂干预措施对心肾结局的比较疗效：网络荟萃分析。
Medicine (Baltimore). 2021 Jul 30;100(30):e26431. doi: 10.1097/MD.0000000000026431.
10
Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.随机临床试验中钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽-1受体激动剂的获益比较：一项网状Meta分析
Minerva Cardiol Angiol. 2023 Apr;71(2):199-207. doi: 10.23736/S2724-5683.22.05900-2. Epub 2022 Feb 23.

本文引用的文献

1
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.在 FLOW 试验中，有 2 型糖尿病和慢性肾病的参与者使用和不使用 SGLT2 抑制剂的司美格鲁肽的影响。
Nat Med. 2024 Oct;30(10):2849-2856. doi: 10.1038/s41591-024-03133-0. Epub 2024 Jun 24.
2
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.KDIGO 2024慢性肾脏病评估与管理临床实践指南
Kidney Int. 2024 Apr;105(4S):S117-S314. doi: 10.1016/j.kint.2023.10.018.
3
13. Older Adults: Standards of Care in Diabetes-2024.13. 老年人：2024年糖尿病护理标准
Diabetes Care. 2024 Jan 1;47(Suppl 1):S244-S257. doi: 10.2337/dc24-S013.
4
Diabetes care in older people: a call for action.老年人的糖尿病护理：行动呼吁。
Lancet Healthy Longev. 2023 Dec;4(12):e657-e659. doi: 10.1016/S2666-7568(23)00234-9.
5
GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.GLP-1 受体激动剂和 SGLT2 抑制剂治疗 2 型糖尿病老年患者：系统评价和荟萃分析。
Diabetes Res Clin Pract. 2021 Apr;174:108737. doi: 10.1016/j.diabres.2021.108737. Epub 2021 Mar 8.
6
Optum Labs: building a novel node in the learning health care system.Optum实验室：构建学习型医疗保健系统中的一个新型节点。
Health Aff (Millwood). 2014 Jul;33(7):1187-94. doi: 10.1377/hlthaff.2014.0038.